We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Amgen (AMGN - Free Report) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%.
The world's largest biotech drugmaker's shares have seen an increase of 10.63% over the last month, surpassing the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2025. The company's upcoming EPS is projected at $5.25, signifying a 5.63% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.86 billion, up 5.64% from the year-ago period.
AMGN's full-year Zacks Consensus Estimates are calling for earnings of $20.87 per share and revenue of $35.23 billion. These results would represent year-over-year changes of +5.19% and +5.41%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.24% rise in the Zacks Consensus EPS estimate. Amgen is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 14.69 right now. This represents a discount compared to its industry average Forward P/E of 20.33.
We can also see that AMGN currently has a PEG ratio of 2.65. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.75 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest close session, Amgen (AMGN - Free Report) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%.
The world's largest biotech drugmaker's shares have seen an increase of 10.63% over the last month, surpassing the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2025. The company's upcoming EPS is projected at $5.25, signifying a 5.63% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.86 billion, up 5.64% from the year-ago period.
AMGN's full-year Zacks Consensus Estimates are calling for earnings of $20.87 per share and revenue of $35.23 billion. These results would represent year-over-year changes of +5.19% and +5.41%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.24% rise in the Zacks Consensus EPS estimate. Amgen is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 14.69 right now. This represents a discount compared to its industry average Forward P/E of 20.33.
We can also see that AMGN currently has a PEG ratio of 2.65. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.75 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.